Classifying individuals at risk for cervical cancer
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
This study is trying to find out if certain genetic markers can help identify people at risk for cervical cancer by analyzing their blood samples and following them for five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Anhui Provincial Hospital Government |
| Locations | 1 site (Hefei, Anhui) |
| Trial ID | NCT06405945 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze genomic risk factors associated with cervical cancer and classify individuals into different risk categories. By utilizing genome-wide association studies, the research will identify genetic markers linked to susceptibility to cervical cancer. Participants will undergo screening colposcopy and provide blood samples for PCR and sequencing to explore potential biomarkers and therapeutics. The study will follow participants for five years to monitor outcomes and validate findings.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18 and older who are considered at average risk for cervical cancer and are willing to participate in follow-up assessments.
Not a fit: Patients with a history of cervical cancer or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and targeted prevention strategies for cervical cancer.
How similar studies have performed: Other studies have shown success in identifying genetic markers for various cancers, suggesting potential for this approach in cervical cancer classification.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects aged \>=18 years at time of consent 2. Intended to undergo screening colposcopy 3. Considered by a physician or healthcare provider as being of "average risk" for cervical cancer 4. Willing to consent to blood draw cervical disease treatments 5. Willing to sonsent to follow-up for five years as per protocol Exclusion Criteria: 1. History of cervical cancer 2. History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 3. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs. 4. Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent 5. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
Where this trial is running
Hefei, Anhui
- The First Affiliated Hospital of USTC — Hefei, Anhui, China (Recruiting)
Study contacts
- Study coordinator: Yingying Wang, Doctor
- Email: yingyingwang@ustc.edu.cn
- Phone: 18652270921
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.